These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9364286)

  • 61. H pylori infection and reflux oesophagitis.
    Kountouras J; Zavos C; Chatzopoulos D
    Gut; 2004 Jun; 53(6):912. PubMed ID: 15138222
    [No Abstract]   [Full Text] [Related]  

  • 62. Prokinetic agents in childen with poor appetite.
    Bekem O; Buyukgebiz B; Aydin A; Ozturk Y; Tasci C; Arslan N; Durak H
    Acta Gastroenterol Belg; 2005; 68(4):416-8. PubMed ID: 16432992
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome.
    Rahman MZ; Ahmed DS; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Barua R; Ishaque SM
    Mymensingh Med J; 2014 Jan; 23(1):105-13. PubMed ID: 24584382
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of orally vs. parenterally administrated trimebutine on gastrointestinal and colonic motility in dogs.
    Buéno L; Hondé C; Pascaud X; Junien JL
    Gastroenterol Clin Biol; 1987; 11(3 Pt 2):90B-93B. PubMed ID: 3609630
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying.
    Ozaki K; Onoma M; Muramatsu H; Sudo H; Yoshida S; Shiokawa R; Yogo K; Kamei K; Cynshi O; Kuromaru O; Peeters TL; Takanashi H
    Eur J Pharmacol; 2009 Aug; 615(1-3):185-92. PubMed ID: 19445919
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The ontogeny of the small intestinal epithelium.
    Lebenthal A; Lebenthal E
    JPEN J Parenter Enteral Nutr; 1999; 23(5 Suppl):S3-6. PubMed ID: 10483884
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Mode of action of trimebutine: involvement if opioid receptors].
    Pascaud X; Petoux F; Roman F; Vauche D; Junien JL
    Presse Med; 1989 Feb; 18(6):298-302. PubMed ID: 2537972
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Review article: evaluation of drugs in experimental gut distension models.
    Pappas TN; Mangel AW; Lawson C
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():54-6. PubMed ID: 10429741
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial.
    Hobson R; Farmer AD; Dewit OE; O'Donnell M; Hacquoil K; Robertson D; Barton ME; Dukes GE
    Neurogastroenterol Motil; 2015 Nov; 27(11):1629-37. PubMed ID: 26348542
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
    Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT
    J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical pharmacology forum: motility agents and the gastrointestinal tract.
    McCallum RW
    Am J Med Sci; 1996 Jul; 312(1):19-26. PubMed ID: 8686725
    [No Abstract]   [Full Text] [Related]  

  • 72. Allergic contact dermatitis due to trimebutine.
    Reyes JJ; Fariña MC
    Contact Dermatitis; 2001 Sep; 45(3):164. PubMed ID: 11553143
    [No Abstract]   [Full Text] [Related]  

  • 73. Travel stress alters the intestinal migrating myoelectric complex in rats: antagonist effect of trimebutine.
    Diop L; Pascaud X; Le Gallou B; Junien JL
    Life Sci; 1992; 50(4):263-71. PubMed ID: 1732698
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice.
    Cenac N; Castro M; Desormeaux C; Colin P; Sie M; Ranger M; Vergnolle N
    Eur J Pain; 2016 May; 20(5):723-30. PubMed ID: 26541237
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Effect of Trimebutine on the Overlap Syndrome Model of Guinea Pigs.
    Hussain Z; Jung DH; Lee YJ; Park H
    J Neurogastroenterol Motil; 2018 Oct; 24(4):669-675. PubMed ID: 30114898
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gastrointestinal neuropharmacology: identification of therapeutic targets.
    Furness JB; Sanger GJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):609-11. PubMed ID: 12482721
    [No Abstract]   [Full Text] [Related]  

  • 77. Some of the challenges in drug development for irritable bowel syndrome.
    Mayer EA
    Gut; 2001 May; 48(5):585-6. PubMed ID: 11302947
    [No Abstract]   [Full Text] [Related]  

  • 78. The pharmacology of gastrointestinal nociceptive pathways.
    Blackshaw LA; Gebhart GF
    Curr Opin Pharmacol; 2002 Dec; 2(6):642-9. PubMed ID: 12482725
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with dual antiemetic and gastroprokinetic activities.
    Hirokawa Y; Yamazaki H; Yoshida N; Kato S
    Bioorg Med Chem Lett; 1998 Aug; 8(15):1973-8. PubMed ID: 9873469
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacology and clinical experience with fedotozine.
    Delvaux M
    Expert Opin Investig Drugs; 2001 Jan; 10(1):97-110. PubMed ID: 11116283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.